Technical Analysis for AKRO - Akero Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 45.36 | -1.22% | -0.56 |
AKRO closed down 1.22 percent on Monday, September 25, 2023, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Oct 1
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | about 6 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Down 2 % | about 9 hours ago |
| 200 DMA Support | about 10 hours ago |
| 200 DMA Resistance | about 10 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/01/2023
Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases with high unmet medical need. The company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Alcohol Clinical Trial Steatohepatitis Hepatitis Metabolic Disease Non Alcoholic Fatty Liver Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Alcohol Clinical Trial Steatohepatitis Hepatitis Metabolic Disease Non Alcoholic Fatty Liver Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 58.38 |
| 52 Week Low | 26.37 |
| Average Volume | 706,695 |
| 200-Day Moving Average | 45.65 |
| 50-Day Moving Average | 46.76 |
| 20-Day Moving Average | 49.60 |
| 10-Day Moving Average | 49.52 |
| Average True Range | 1.94 |
| RSI (14) | 35.90 |
| ADX | 26.47 |
| +DI | 22.63 |
| -DI | 27.16 |
| Chandelier Exit (Long, 3 ATRs) | 47.94 |
| Chandelier Exit (Short, 3 ATRs) | 50.82 |
| Upper Bollinger Bands | 52.91 |
| Lower Bollinger Band | 46.29 |
| Percent B (%b) | -0.14 |
| BandWidth | 13.35 |
| MACD Line | 0.13 |
| MACD Signal Line | 0.82 |
| MACD Histogram | -0.6889 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 46.79 | ||||
| Resistance 3 (R3) | 46.82 | 46.38 | 46.55 | ||
| Resistance 2 (R2) | 46.38 | 46.02 | 46.36 | 46.47 | |
| Resistance 1 (R1) | 45.87 | 45.79 | 45.65 | 45.84 | 46.39 |
| Pivot Point | 45.43 | 45.43 | 45.32 | 45.41 | 45.43 |
| Support 1 (S1) | 44.92 | 45.07 | 44.70 | 44.89 | 44.33 |
| Support 2 (S2) | 44.48 | 44.84 | 44.46 | 44.25 | |
| Support 3 (S3) | 43.97 | 44.48 | 44.17 | ||
| Support 4 (S4) | 43.94 |
